Siringoma condroide simulando un carcinoma basocelular / Chondroid Syringoma Mimicking Basal Cell Carcinoma

No disponible

Estudio ecográfico de metástasis cutáneas de origen visceral / Ultrasound in the Evaluation of Cutaneous Metastases of Internal Tumors

No disponible

FR- Riesgo de cáncer cutáneo no melanoma en pacientes hemodializados / FR- Risk of Nonmelanoma Skin Cancer in Patients on Hemodialysis

No disponible

Placa hiperqueratósica asintomática en glande en un varón de mediana edad / Asymptomatic Hyperkeratotic Plaque on the Glans in a Middle-Aged Man

No disponible

Un tumor rosado, hiperplasia angiolinfoide con eosinofilia / A Pink Tumor: Angiolymphoid Hyperplasia With Eosinophilia

No disponible

A microfluidic platform for size-dependent generation of droplet interface bilayer networks on rails.

Droplet interface bilayer (DIB) networks are emerging as a cornerstone technology for the bottom up construction of cell-like and tissue-like structures and bio-devices. They are an exciting and versatile model-membrane platform, seeing increasing use in the disciplines of synthetic biology, chemical biology, and membrane biophysics. DIBs are formed when lipid-coated water-in-oil droplets are brought together-oil is excluded from the interface, resulting in a bilayer. Perhaps the greatest feature of the DIB platform is the ability to generate bilayer networks by connecting multiple droplets together, which can in turn be used in applications ranging from tissue mimics, multicellular models, and bio-devices. For such applications, the construction and release of DIB networks of defined size and composition on-demand is crucial. We have developed a droplet-based microfluidic method for the generation of different sized DIB networks (300-1500 pl droplets) on-chip. We do this by employing a droplet-on-rails strategy where droplets are guided down designated paths of a chip with the aid of microfabricated grooves or "rails," and droplets of set sizes are selectively directed to specific rails using auxiliary flows. In this way we can uniquely produce parallel bilayer networks of defined sizes. By trapping several droplets in a rail, extended DIB networks containing up to 20 sequential bilayers could be constructed. The trapped DIB arrays can be composed of different lipid types and can be released on-demand and regenerated within seconds. We show that chemical signals can be propagated across the bio-network by transplanting enzymatic reaction cascades for inter-droplet communication.

Microfluidic generation of droplet interface bilayer networks incorporating real-time size sorting in linear and non-linear configurations.

In this study, a novel droplet based microfluidic method for the generation of different sized droplet interface bilayers is reported. A microfluidic platform was designed, which allows the generation and packing of picoliter lipid coated water droplets. Droplets were generated by hydrodynamic focusing coupled with selective transport along grooves according to their size. A trapping structure at the end of the groove and a fine control of the flow pressures allowed for the droplets to be successfully trapped and aligned on demand. This technology facilitates the fine control of droplet size production as well as the generation of extended networks from a variety of lipids including 1,2-diphytanoyl-sn-glycero-3-phosphocholine and 1,2-dioleoyl-sn-glycero-3-phosphocholine in linear and non-linear configurations, which is vital to the application of Droplet Interface Bilayers to biological network construction on-chip.

[Zinc intake deficiency and colorectal cancer: what is the situation in our population?]. / Déficit en la ingesta de zinc y cáncer colorrectal: qué pasa en nuestra población?

INTRODUCTION AND OBJECTIVES: Various experimental studies have shown that a deficient intake of zinc increases the proliferation of cells, the effect of carcinogens and the progression of colonic adenomas to carcinomas. The purpose of our study is to determine whether this relationship between zinc intake deficit and colorectal cancer can be found in our population. METHODS: The study included 100 cases of colorectal cancer which were compared with 200 control patients (76% hospital admissions, 22% in the community and 2% with normal colonoscopy). The sampling of cases was done consecutively without use of probabilities and with the later application of a stratified matching design. For data collection purposes, a food survey form was used. For the determination of a deficient zinc intake this was compared with the values of the United States' Recommended Dietary Allowance (RDA). Deficient zinc intake was defined as values lower than 75% of RDA. Statistical calculations were effected by calculating chi-squared. The level of statistical significance was set at p < 0.05. RESULTS: Seventy-nine patients with cancer (79%) presented zinc intake deficiency, whereas the figure for the control group was 142 individuals (71%). From these data, a chi-square obtained was 2.19, corresponding to a p > 0.1. CONCLUSIONS: Despite the evidence of the experimental studies, we have been unable to identify any relationship between deficient zinc intake and colorectal cancer in our population.

Déficit en la ingesta de zinc y cáncer colorrectal: ¿qué pasa en nuestra población? / Zinc intake deficit and colorectal cancer: what is the situation in our population?

Introducción y objetivos: Diversos estudios experimentales evidencian que el déficit en la ingesta de zinc aumenta la proliferación celular, el efecto de los carcinogenos y la progresión de adenomas a carcinomas cólicas: El objetivo de nuestro trabajo es precisar si esta relación entre déficit en la ingesta de zinc y cáncer colorrectal se evidencia en nuestra población.Métodos: El estudio incluyó 100 casos de cáncer colorrectal que fueron comparados con 200 controles (76 por ciento hospitalarios, 22 por ciento comunitarios, 2 por ciento con colonoscopia normal). El muestreo de los casos fue consecutivo no probabilístico, utilizándose posteriormente un diseño por apareamiento estratificado. Para la obtención de datos fue utilizada una encuesta alimentaria. Para la determinación del déficit en la ingesta de zinc se comparó ésta con los valores de la "ración dietética recomendada" (recommended dietary allowance o RDA norteamericana). Se definió como déficit en la ingesta de zinc a los valores inferiores al 75 por ciento de la RDA. Los cálculos estadísticos se realizaron mediante el cálculo de la ji-cuadrado. El nivel de significación estadística se estableció en p 0,1.Conclusiones: A pesar de las evidencias de los estudios experimentales, no hemos podido encontrar relación alguna entre el déficit en la ingesta de zinc y el cáncer colorrectal en nuestra población (AU)

Introduction and objectives: Various experimental studies have shown that a deficient intake of zinc increases the proliferation of cells, the effect of carcinogens and the progression of colonic adenomas to carcinomas. The purpose of our study is to determine whether this relationship between zinc intake deficit and colorectal cancer can be found in our population. Methods: The study included 100 cases of colorectal cancer which were compared with 200 control patients (76% hospital admissions, 22% in the community and 2% with normal colonoscopy). The sampling of cases was done consecutively without use of probabilities and with the later application of a stratified matching design. For data collection purposes, a food survey form was used. For the determination of a deficient zinc intake this was compared with the values of the United States Recommended Dietary Allowance (RDA). Deficient zinc intake was defined as values lower than 75% of RDA. Statistical calculations were effected by calculating chisquared. The level of statistical significance was set at p < 0.05. Results: Seventy-nine patients with cancer (79%) presented zinc intake deficiency, whereas the figure for the control group was 142 individuals (71%). From these data, a chi-square obtained was 2.19, corresponding to a p > 0.1. Conclusions: Despite the evidence of the experimental studies, we have been unable to identify any relationship between deficient zinc intake and colorectal cancer in our population (AU)

Déficit en la ingesta de iodo y cáncer colorrectal / Iodine deficiency and colo-rectal cancer

Fundamentos: Recientemente se ha comunicado que el déficit en la ingesta de iodo disminuiría el riesgo de padecer cáncer colorrectal. El objetivo de nuestro estudio ha sido comprobar si este papel protector frente al cáncer colorrectal del déficit en la ingesta de iodo dietético está presente en nuestra población.Métodos: El estudio incluyó 100 casos de cáncer colorrectal que fueron comparados con 200 controles (76 por ciento hospitalarios, 22 por ciento comunitarios, 2 por ciento con colonoscopia normal). El muestreo de los casos fue consecutivo no probabilistico, utilizándose posteriormente un diseño por apareamiento estratificado. Para la obtención de datos fue utilizada una encuesta alimentaria. Para la determinación del déficit en la ingesta de iodo se comparó esta con los valores de la "recomendación de ingesta diaria" (RID). Se definió como déficit en la ingesta de iodo a los valores inferiores al 100 por ciento de la RID. Los cálculos estadísticos se realizaron mediante el cálculo de la Ji-cuadrado. El nivel de significación estadística se estableció en p<0.05.Resultados: Cincuenta y dos pacientes con cáncer (52 por ciento) presentaron déficit en la ingesta de iodo, mientras que en el grupo control lo hicieron 67 individuos/as (34 por ciento). Con estos datos se obtuvo una Ji-cuadrado de 9, correspondiéndole una p< 0.005.Conclusiones: En nuestra población, el déficit en la ingesta de iodo no sólo no protege del cáncer colorrectal sino que se asociaría a un mayor riesgo para esta neoplasia. A pesar de ello, creemos que antes de recomendar el uso de sal iodada o alimentos ricos en iodo (pescado, mariscos) la relación entre déficit en la ingesta de iodo y cáncer colorrectal debe refrendarse en estudios experimentales y de intervención dietética (AU)

[Results of treating cervical metastases of an unknown primary tumor. A report of 29 cases]. / Resultados del tratamiento de las metástasis cervicales de primario no filiado. A propósito de 29 casos.

A retrospective study was made of 29 patients with cervical metastasis of an unknown primary tumor. Sixteen patients received local treatment with surgery and radiotherapy (group A) and 13 patients were treated with induction chemotherapy, surgery and radiotherapy (group B). All patients responded. Local recurrence occurred in 21.4% of group A and 20% of group B. The frequency of distant metastases was similar (18.8% vs 15.4%). The mean survival time of 68 months in group A was longer than the 40 months of group B, and the a 2-year survival rate was 81% in group A and 67% in group B. The 5-year survival was better in group B (56% vs 40%). The primary tumor was identified twice as often in the patients who received only local treatment (group A 37.5% and group B 15.4%). Detection of the primary tumor was the only factor that significantly influenced patient survival.

[Radiotherapy alone versus neo-adjuvant chemotherapy and irradiation in the treatment of carcinoma of the cavum]. / Radioterapia exclusiva frente a quimioterapia neoadyuvante más radioterapia en el tratamiento de los carcinomas de cávum.

Radiation therapy is the usual treatment for nasopharyngeal carcinoma. However, in recent years the use of neoadyuvant chemotherapy in the treatment of local and regionally advanced carcinoma has been investigated. We report the results of a retrospective study of two treatments used in our center. The study included 68 patients: 34 (group A) who received radiotherapy alone and 34 (group B) who received neoadyuvant chemotherapy before radiotherapy. In group A, 70.6% achieved a complete clinical response: 23.5% relapsed: 5 patients presented distant metastases. Survival rates at 5 and 10 years were 53% and 27% respectively; the disease-free survival was 71.4% at 5 years and 54% at 10 years. In group B, the complete clinical response rate to neoadyuvant chemotherapy was 35.3%, which increased to 73.5% when the treatment was complemented with radiotherapy. The relapse rate was 14.7%; the survival rates at 5 and 10 years were 49.5% and 49%, respectively; and the disease-free survival was 77.2% at 5 and 10 years.

Algunos aspectos epidemiológicos de la miastenia gravis en Cuba / Some epidemiological aspects of Myasthenia Gravis in Cuba incidence mortality and lehality for myastenia gravis in Cuba

Se estimaron las tasas de incidencia, prevalencia, mortalidad y letalidad pormiastenia gravis en Cuba, previo estudios epidemiológicos desarrollados en 8 de las 14 provincias del país: Pinar del Río, Ciudad de La Habana, La Habana, Matanzas, Cienfuegos, Sancti-Spíritus, Camaguey y Guantánamo. Las tasas de incidencia, prevalencia y mortalidad dieron de 4,52, 29,22 y 0,72 por millón de habitantes respectivamente. La tasa de letalidad fue de 10,77

[Metastasis of breast carcinoma in parotid. A case report and review of the literature]. / Metástasis de carcinoma de mama en parótida: a propósito de un caso y revisión de la bibliografía.

Breast cancer is a systemic illness that sometimes affects the ENT area. We report a case of parotid tumor with progressive growth, which rarely originals in the ENT area. We review the literature and discuss the treatment.

[Unexpected hypoglycemia in hospitalized patients]. / Hipoglucemia inesperada en pacientes hospitalizados.

We analyze 40 episodes of unsuspected hypoglycemia (glycemia < or = 3.30 mmol/l) in 36 in patients during seven months in a tertiary hospital. Only 22% of them were diabetics, the rest had other risk-factors such as malnutrition (47%), infections (47%), liver diseases (22%), renal failure (19%) or neoplasias (17%). Only 14% of the subjects had symptoms related to hypoglycemia, and only 27% received treatment. There were no significative differences between those patients over 65 years and the younger ones. Hypoglycemia was not the apparent cause of death in any of the patients, but hospital mortality of these patients was 25%, and it was related with the number of risk factors. We conclude that hypoglycemia in hospitalized patients is often unnoticed, as it appears with diseases other than diabetes, and that it is related with a high mortality in patients with severe diseases.